LI
LIA.F LivaNova PLC
- Market cap
- EUR 4.46B
- P/E
- 27.0x
- P/B
- 3.68x
- ROE
- 16.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LIA.F undervalued?
Graham numberLIA.F trades 110.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LivaNova PLC fundamental analysis
No fundamental analysis for LivaNova PLC yet.
LivaNova PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LivaNova PLC
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VN…
Full company profileLivaNova PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
LivaNova PLC annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.21B | 1.01B | 1.11B | 1.08B | 934M | 1.04B | 1.02B | 1.15B | 1.25B | 1.39B | 1.53B |
| Gross Profit | 704M | 652M | 734M | 745M | 618M | 706M | 707M | 756M | 853M | 940M | 1.04B |
| Operating Income | 67.2M | 128M | 86.3M | 48.0M | -43.0M | -800K | 52.7M | 21.5M | 129M | 199M | 159M |
| EBITDA | - | 212M | -168M | -87.6M | -222M | -6.90M | 31.0M | 38.5M | 203M | -112M | 224M |
| Net Income | -62.8M | -25.1M | -189M | -155M | -345M | -136M | -86.2M | 17.5M | 63.2M | -242M | 220M |
| EPS | - | -0.52 | -3.93 | -3.20 | -7.09 | -2.55 | -1.61 | 0.33 | 1.16 | -4.44 | 4.00 |
| Balance Sheet | |||||||||||
| Total Assets | 2.34B | 2.50B | 2.55B | 2.41B | 2.41B | 2.20B | 2.29B | 2.43B | 2.51B | 2.61B | 2.71B |
| Total Liabilities | 636M | 689M | 1.05B | 1.03B | 1.29B | 906M | 1.09B | 1.15B | 1.19B | 1.41B | 1.34B |
| Shareholders' Equity | 1.71B | 1.82B | 1.50B | 1.38B | 1.12B | 1.29B | 1.21B | 1.28B | 1.32B | 1.20B | 1.37B |
| Cash & Short-term Investments | 39.8M | 93.6M | 47.2M | 61.1M | 253M | 208M | 214M | 267M | 429M | 636M | 563M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 90.2M | 91.3M | 120M | -91.1M | -79.4M | 103M | 69.9M | 39.7M | 183M | 254M | 207M |
| Capital Expenditure | 38.4M | 32.9M | 37.2M | 24.7M | 35.0M | 25.5M | 26.5M | 31.2M | 47.1M | 81.1M | 102M |
| Free Cash Flow | - | 57.2M | 82.5M | -119M | -114M | 77.0M | 43.4M | 8.46M | 136M | 173M | 105M |
| Ratios | |||||||||||
| ROE | -3.7% | -1.4% | -12.6% | -11.2% | -30.8% | -10.5% | -7.1% | 1.4% | 4.8% | -20.2% | 16.0% |
| ROA | -2.7% | -1.0% | -7.4% | -6.4% | -14.3% | -6.2% | -3.8% | 0.7% | 2.5% | -9.3% | 8.1% |
| Net Profit Margin | -5.2% | -2.5% | -17.1% | -14.3% | -36.9% | -13.1% | -8.4% | 1.5% | 5.0% | -17.5% | 14.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
LivaNova PLC dividends
LivaNova PLC has not paid dividends in the last 9 fiscal years.
Who owns LivaNova PLC
- Insiders 0.41%
- Institutions 99.59%
- Public & others 0.00%
- Shares outstanding 55.1M
- Free float 54.8M
LivaNova PLC company profile
- Company name
- LivaNova PLC
- Ticker
- LIA.F
- ISIN
- GB00BYMT0J19
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 3,300
- Fiscal year end
- December
- Address
- 5220 Valiant Court, Gloucester, United Kingdom, GL3 4FE
- Phone
- 44 1452 638 500
- Website
- livanova.com
About LivaNova PLC
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.
LivaNova PLC management
10- Mr. Vladimir A. MakatsariaCEO & Director · born 1973
- Mr. Alex Shvartsburg C.M.A.Chief Financial Officer · born 1970
- Ms. Natalia Sergeyevna KozminaChief Human Resources Officer · born 1971
- Mr. Ahmet Tezel Ph.D.Chief Innovation Officer · born 1975
- Ms. Lindsey LittleVP & Chief Accounting Officer
- Briana GotlinVice President of Investor Relations
- Ms. Anne M. LiddyChief Legal Officer · born 1976
- Deanna WilkeVice President of Corporate Communications
- Mr. Philip KowalczykChief Strategy & Corporate Development Officer
- Mr. Paul R. BuckmanPresident of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement · born 1956